|
1
|
Kudryavtsev KV, Ivantcova PM, Muhle-Goll C, Churakov AV, Sokolov MN, Dyuba AV, Arutyunyan AM, Howard JAK, Yu CC, Guh JH, Zefirov NS, Bräse S. Menthols as Chiral Auxiliaries for Asymmetric Cycloadditive Oligomerization: Syntheses and Studies of β-Proline Hexamers. Org Lett 2015; 17:6178-81. [PMID: 26624275 DOI: 10.1021/acs.orglett.5b03154] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
To produce a novel class of structurally ordered poly-β-prolines, an emergent method for synthesizing chiral β-peptide molecular frameworks was developed based on 1,3-dipolar cycloaddition chemistry of azomethine ylides. Functionalized short β-peptides with up to six monomeric residues were efficiently synthesized in homochiral forms using a cycloadditive oligomerization approach. X-ray, NMR, and CD structural analyses of the novel β-peptides revealed secondary structure features that were generated primarily by Z/E-β-peptide bond isomerism. Anticancer in cellulo activity of the new β-peptides toward hormone-refractory prostate cancer cells was observed and was dependent on the absolute configuration of the stereogenic centers and the chain length of the β-proline oligomers.
Collapse
Affiliation(s)
- Konstantin V Kudryavtsev
- Department of Chemistry, M.V. Lomonosov Moscow State University , Leninskie Gory 1/3, Moscow 119991, Russian Federation.,Institute of Physiologically Active Compounds, Russian Academy of Sciences , Chernogolovka, Moscow Region 142432, Russian Federation
| | - Polina M Ivantcova
- Department of Chemistry, M.V. Lomonosov Moscow State University , Leninskie Gory 1/3, Moscow 119991, Russian Federation
| | - Claudia Muhle-Goll
- Institute of Organic Chemistry, Karlsruhe Institute of Technology , Fritz-Haber-Weg 6, Karlsruhe 76131, Germany
| | - Andrei V Churakov
- Institute of General and Inorganic Chemistry, Russian Academy of Sciences , Leninskii prosp. 31, Moscow 119991, Russian Federation
| | - Mikhail N Sokolov
- Department of Chemistry, M.V. Lomonosov Moscow State University , Leninskie Gory 1/3, Moscow 119991, Russian Federation
| | - Artem V Dyuba
- A.N. Belozersky Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University , Leninskie Gory 1/40, Moscow 119991, Russian Federation
| | - Alexander M Arutyunyan
- A.N. Belozersky Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University , Leninskie Gory 1/40, Moscow 119991, Russian Federation
| | - Judith A K Howard
- Department of Chemistry, University of Durham , South Road, Durham DH1 3LE, U.K
| | - Chia-Chun Yu
- School of Pharmacy, National Taiwan University , Linsen S. Rd. 33, Taipei 100, Taiwan
| | - Jih-Hwa Guh
- School of Pharmacy, National Taiwan University , Linsen S. Rd. 33, Taipei 100, Taiwan
| | - Nikolay S Zefirov
- Department of Chemistry, M.V. Lomonosov Moscow State University , Leninskie Gory 1/3, Moscow 119991, Russian Federation.,Institute of Physiologically Active Compounds, Russian Academy of Sciences , Chernogolovka, Moscow Region 142432, Russian Federation
| | - Stefan Bräse
- Institute of Organic Chemistry, Karlsruhe Institute of Technology , Fritz-Haber-Weg 6, Karlsruhe 76131, Germany.,Institute of Toxicology and Genetics, Karlsruhe Institute of Technology , Hermann-von-Helmholtz-Platz 1, Eggenstein-Leopoldshafen 76344, Germany
| |
Collapse
|
|
2
|
Cornford P. Evolution of Docetaxel-Based Therapy for Metastatic Castrate-Resistant Prostate Cancer. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/j.bjmsu.2010.08.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Until the publication of the SWOG 99–16 [1] and TAX 327 [2] trials in 2004, urologists understood that only purely palliative treatment was available for men with prostate cancer that was progressive despite androgen deprivation. However, following the establishment of docetaxel-based chemotherapy as an active treatment option for most men with metastatic disease, researchers have focused their questions on the optimal timing of treatment. Should docetaxel be considered after one or two lines of hormone manipulation? Is it necessary to wait until the patient has bone pain? In latter years, the research focus has widened to embrace second-line and even third-line chemotherapy for this patient group, raising the possibility of advanced prostate cancer being managed as a chronic condition. This article looks at the evolution of docetaxel-based chemotherapy in advanced prostate cancer, and considers the next likely developments.
Collapse
Affiliation(s)
- Philip Cornford
- Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, United Kingdom
| |
Collapse
|